Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, primarily Alzheimer’s disease. The company’s main commercial product is ZUNVEYL (benzgalantamine), an oral tablet formulation approved by the FDA in July 2024 for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. ZUNVEYL is a next-generation acetylcholinesterase inhibitor that binds neuronal nicotinic receptors, specifically the alpha-7 subtype, to support cognition. The company launched ZUNVEYL commercially in the United States in March 2025, targeting the long-term care market with a specialty sales force focused on nursing homes and LTC physicians. Alpha Cognition also maintains pre-clinical development programs, including a sublingual formulation of ALPHA-1062 for cognitive impairment associated with mild traumatic brain injury and a combination therapy of ZUNVEYL with memantine for moderate-to-severe Alzheimer’s disease. The company has entered into a licensing agreement with CMS International Development and Management Limited for the development and commercialization of ZUNVEYL in Asia (excluding Japan), Australia, and New Zealand. Alpha Cognition previously held rights to assets such as ALPHA-0602, ALPHA-0702, and ALPHA-0802 (Progranulin and Progranulin GEMs) for conditions including ALS and SMA, but terminated its licensing agreement for these assets while retaining royalty rights.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage alphacognition.com
Sector Healthcare IR page alphacognition.com/investors
Tags
alzheimer's disease, neurodegenerative diseases, acetylcholinesterase inhibitors, benzgalantamine, long-term care, mild traumatic brain injury, oral tablets, sublingual formulations, combination therapy, memantine, ZUNVEYL, ALPHA-1062, ALPHA-1062IN, ALPHA-0602, ALPHA-0702, ALPHA-0802, Progranulin, Progranulin GEMs, CMS International Development and Management Limited, CMSI
Press page alphacognition.com/investors/news

Metrics

Valuation  
Market cap $ 181.036M
Market cap (USD) $ 181.036M
P/E -7.04
PEG —
P/BV 3.67
P/S 8.96
P/OCF -5.95
P/FCF -5.87
Dividend yield —
Turnover / mcap —
Returns  
ROE -39.8%
ROI -33.1%
ROIC -27.2%
Profit margin -202.2%
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -76.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 10.22M — 0 0 0
Net profit -20.67M -14.637M -13.764M -12.115M -19.545M
Free cash flow -20.674M -7.782M -8.8M -9.247M -9.943M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 6.5 5.89 — — —
Price performance 12m 0.1 — — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 4.24M
Cash and deposits (USD) 2.08M 1.4M 48.5M 66M
Intangible assets (USD) — 532,010 412,969 391,423
Cash flow detail
Operating cash flow (USD) — -8.8M -7.76M -20.4M
Purchases of property, plant and equipment (USD) — — -26,701 -293,489
Change in receivables (cash effect) (USD) — — — -4.24M
Change in inventories (cash effect) (USD) — — -615,133 -4.51M
Change in payables (cash effect) (USD) — -1.45M 1.05M 6.52M
Interest paid (cash effect) (USD) — -59,777 -37,754 -4,894
Share-based compensation (USD) — 2.37M 979,799 4.92M
Operating cash flow before change in receivables (USD) — — — -16.1M
Free cash flow (OCF - PPE - intangibles) (USD) — — -7.78M -20.7M
Income detail
Research and development expense (USD) — 4.88M 3.92M 1.87M
Total comprehensive income (USD) — -13.8M -14.6M —
Comprehensive income to owners (USD) — -13.8M -14.6M —
Reported Aug 12, 2024 Mar 31, 2025 Mar 31, 2025 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 5, 2026, the board of directors (the “Board”) of Alpha Cognition Inc. (the “Company”) appointed Caren Deardorf as a director of the Company effective November 11, 2026.

Ms. Deardorf is a biotechnology executive and public company director with more than 30 years of experience spanning commercialization, corporate strategy, portfolio prioritization, business development, and company building. She has helped organizations create and preserve value through category & brand leadership, development-to commercial transitions, portfolio decisions, out-licensing, and M&A pathways. Ms. Deardorf is currently Chief Business and Strategy Officer at Neutrolis Inc., since August of 2025, where she is responsible for leading business development, clinical program strategy, and commercial/operational build for a private autoimmune company in transition to clinical stage. Prior to that, she served as Chief Commercial and Strategy Officer at Editas Medicine (2023-2025), Chief Commercial and Strategy Officer at Magenta Therapeutics (2021-2023) and Chief Commercial Officer at Ohana Biosciences (2019-2021). Ms.

Financial Statements Request Form

Form of Proxy

Notice Regarding Availability of Proxy Materials

2026 Proxy Statement

2025 Annual Statement

Investors

Quick Links

View Video

Read More

Latest News

View All

View All

TSX-V: ACI

15 min delay

Last$9.81

Change$0.13

Open9.78

Vol543872

High9.91

Low9.67

Stock Information

Investor Relations

PJ Kelleher, LifeSci Advisors [email protected] [email protected]

Investors

Quick Links

View Video

Read More

Latest News

View All

View All

TSX-V: ACI

15 min delay

Last$9.81

Change$0.13

Open9.78

Vol543872

High9.91

Low9.67

Stock Information

Prompts

Alpha Cognition Inc. (ticker ACOG), listed in United States.

Company History

Date Change Detail
May 1, 2020 Renamed Neurodyn Cognition Inc. → ALPHA COGNITION INC.

ETFs Holding Alpha Cognition Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 16,242 $ 127.175K Nov 16, 2026